Information Provided By:
Fly News Breaks for November 7, 2019
PBYI
Nov 7, 2019 | 06:37 EDT
Barclays analyst Gena Wang lowered her price target for Puma Biotechnology to $6 from $9 and keeps an Underweight rating on the shares. Puma reported Q3 Nerlynx revenue of $53.6M, below the consensus of $59.0M, and lowered its 2019 guidance for the second time to $205M-$210M from $220M-$240M, Wang tells investors in a research note. The analyst continues to see a limited growth outlook in extended adjuvant setting as well as metastatic HER2+ breast cancer.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.